Quinn Emanuel Urquhart & Sullivan, LLP, Life Sciences | Chambers USA Profile

Regional Rankings
Global
Asia-Pacific
Brazil
Canada
Europe
France
Germany
Greater China Region
Latin America
UK
UK Bar
USA
Specialist Rankings
NewLaw
Crisis & Risk Management
FinTech
GC Influencers
High Net Worth
Litigation Support
Spotlight Rankings
USA: Spotlight
Chambers Autumn Release is now live Learn more
Articles
Global Practice Guides
Expert Focus
Diversity, Equity and Inclusion
Legal Articles
Events
Upcoming Events
Browse All Events
Event Sponsorship
About Our Events
Chambers Autumn Release is now live Learn more
Amplify your presence
Profile Platform
Amplify your ranking and be more discoverable
Includes:

Online Profile

Referee Management

Research Analytics

Marketing Toolkit

Plaques
Improve your performance
Insight
Improve your ranking with unique market insight
Includes:

Client and Market Intelligence

Client Intelligence

Rankings Data Hub

Business Intelligence
Showcase your expertise
Global Practice Guides
Highlight your subject matter expertise
Expert Focus
Provide commentary on key legal matters
In-depth Overviews
Events Sponsorship
Links to other Chambers sites
Global Practice Guides
Chambers Associate
Chambers Student
Chambers Autumn Release is now live Learn more
Submissions
Guide Launch Dates
Methodology
Research Schedule
Research Team
Submissions Process
Chambers Autumn Release is now live Learn more
Help
My Account

Chambers Review

Provided by Chambers

Life Sciences - USA - Nationwide

4

Band 4

What the team is known for

Quinn Emanuel Urquhart & Sullivan, LLP boasts a strong team of litigators able to assist firms on patent interference, Hatch-Waxman and product liability cases.

Notable practitioners

Victoria Maroulis, F. Dominic Cerrito, David Bilsker and Raymond N. Nimrod are key contacts.

View ranking table

Work Highlights

Provided by Quinn Emanuel Urquhart & Sullivan, LLP

Quinn Emanuel Urquhart & Sullivan, LLP obtained a complete victory on behalf of Natera, a market-leading molecular diagnostics company, invalidating three Stanford University patents licensed to and asserted by CareDx, a developer of commercial tests for kidney transplant rejections.